• Home
  • Media
  • Press Releases

Press Releases

Julphar Q3

Gulf Pharmaceutical Industries Julphar maintains sales growth after successful market reentry across GCC

- Julphar announces a 10% increase in sales compared to Q2 2020 - Company continues transformational journey with strategic turnaround on track

Gulf Pharmaceutical Industries Julphar Reports Financial Results for Q2 2020

- Julphar announces 90% increase in sales in comparison to Q2 2019 - Strong result improvement with 6% EBITDA margin in Q2 2020

Gulf Pharmaceutical Industries (Julphar) rights issue oversubscribed by 2.3 times

- Julphar launched AED 500 million rights issue at an offer price of AED 1 per share on 29th June 2020 - Total bids received from existing rightsholders stood at AED 1.14 billion on application which closed on 12th July 2020

Julphar resumes sales of products in Bahrain and Kuwait

After an inspection of Julphar facilities, the Gulf Health Council and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait has lifted the temporary suspension on the export of Julphar products to Bahrain and Kuwait
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.